

In France, the offering and sale of Cellectis' shares described below will be made exclusively by way of a private placement to qualified investors, pursuant to article L. 411-2 of the French Code monétaire et financier and applicable rules and regulations. They do not constitute a public offering within the meaning of article L. 411-1 of the French Code monétaire et financier and no prospectus will be filed with the Autorité des marchés financiers.

This announcement and the information that it sets forth do not constitute a subscription offer, or any solicitation of an offer to purchase or subscribe, for shares of Cellectis in the United States or in any other jurisdiction where it may be subject to restrictive regulations. Securities cannot be offered or sold in the United States in the absence of registration or an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Cellectis shares have not been and will not be registered under the Securities Act and Cellectis has no intention of making a public offering for its shares in the United States.

The distribution of this document may, in several countries, be subject to specific regulations. Persons into whose possession this document comes should inform themselves about potential local restrictions and comply with them.

# Successful capital increase

**Paris, October 21, 2009** – Cellectis S.A. announces its successful capital increase, as launched on October 14, for which the terms and conditions are set forth below:

## Characteristics of the issuance

Capital increase without preferential subscription right, exclusively to qualified investors within the meaning of article L.411-2 of the French *Code monétaire et financier*.

Issuance of 1,914,000 new shares with a par value of  $\in 0.05$  each.

Issuance price: €11.50 per share

Gross proceeds from the issuance of the new shares: €22 011 000

Number of shares issued prior to the capital increase: 9 670 316

Number of shares issued after the capital increase: 11 584 316

Use of proceeds: This transaction is intended to reinforce shareholders' equity to enable Cellectis to continue its organic development (in particular through increasing its marketing sales force for Research tools, the intensification of its clinical and preclinical development and the development of its IT systems). The transaction may also enable Cellectis to finance all or part of potential acquisitions aimed at reinforcing its position downstream in the value chain.

Lock-up for the Company: 180 days subject to customary exceptions.

This transaction will increase Cellectis' free float from 31% to approximately 43 %.

The selling shareholders chose not to sell any of their shares at this price.



### Indicative schedule

Issuance and settlement and delivery date – the issuance and settlement and delivery date for the new shares is scheduled to take place on October 23, 2009.

Admission of the New Shares to trading – The New Shares will be subject to an application for admission to trading on the Alternext Paris market of NYSE Euronext. They will be admitted on the same trading line as the existing shares and will be entirely fungible with them as from their admission to trading. The date of admission to trading on the Alternext Paris market of NYSE Euronext is expected to take place on October 23, 2009.

Cellectis' shares are admitted to trading on the Alternext Paris market of NYSE Euronext.

ISIN Code: FR0010425595 Mnemonic: ALCLS

Website: www.cellectis.com

This transaction was led by NATIXIS acting in its capacity as Sole Bookrunner and Sole Lead Manager.

#### About Cellectis S.A.

Cellectis SA is a global leader in genome industry and genome surgery. The company is specialized in the development and production of meganuclease dedicated to the *in vivo* surgery of genomes that are used in the therapeutical, agri-food, bioproduction and research fields. The company has signed over 50 industrial agreements worldwide with pharmaceutical laboratories, agrochemical groups and biotechnological companies, and over 20 partnerships with academic teams. Since its creation, the company has raised over 50 million euros in private and public funds and is listed on the Alternext market of the NYSE Euronext (code: ALCLS). For further information on Cellectis, please visit our website: www.cellectis.com

#### For any additional information, please contact

Cellectis S.A. Marc Le Bozec CFO + 33 (0)1 41 83 99 00 investors@cellectis.com Cellectis S.A. Sylvie Delassus Senior VP, Corporate Communication + 33 (0)1 41 83 99 00 sylvie.delassus@cellectis.com

Alize RP Caroline Carmagnol +33 (0) 6 64 18 99 59 caroline@alizerp.com



#### **IMPORTANT INFORMATION**

THE OFFERING AND SALE OF CELLECTIS' SHARES WILL BE MADE EXCLUSIVELY BY WAY OF A PRIVATE PLACEMENT TO QUALIFIED INVESTORS, PURSUANT TO ARTICLE L. 411-2 OF THE FRENCH CODE MONÉTAIRE ET FINANCIER AND THE APPLICABLE RULES AND REGULATIONS. THEY DO NOT CONSTITUTE A PUBLIC OFFERING WITHIN THE MEANING OF ARTICLE L. 411-1 OF THE FRENCH CODE MONÉTAIRE ET FINANCIER.

THIS PRESS RELEASE DOES NOT CONSTITUTE AND SHOULD NOT BE INTERPRETED TO CONSTITUTE A PUBLIC OFFER, AN OFFER TO SUBSCRIBE OR TO SELL OR AS SOLICITING THE INTEREST OF THE PUBLIC WITH A VIEW TO MAKING A PUBLIC OFFER.

THIS PRESS RELEASE DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF DIRECTIVE 2003/71/EC OF THE EUROPEAN PARLIAMENT AND COUNCIL OF NOVEMBER 4, 2003 (AS IMPLEMENTED IN EACH OF THE MEMBER OF THE EUROPEAN ECONOMIC AREA).

IN RELATION TO EACH MEMBER OF THE EUROPEAN ECONOMIC AREA WHICH HAS IMPLEMENTED THE PROSPECTUS DIRECTIVE (EACH, A "RELEVANT MEMBER STATE"), NO ACTION HAS BEEN TAKEN OR WILL BE TAKEN TO PERMIT A PUBLIC OFFER OF CELLECTIS SHARES THAT WOULD REQUIRE THE PUBLICATION OF A PROSPECTUS IN A RELEVANT MEMBER STATE. THEREFORE, THE SHARES CAN ONLY BE OFFERED IN THE RELEVANT MEMBER STATES TO:

(A) LEGAL ENTITIES WHICH ARE AUTHORIZED OR REGULATED TO OPERATE IN THE FINANCIAL MARKETS AND NON-AUTHORIZED OR NON-REGULATED ENTITIES WHOSE CORPORATE PURPOSE IS SOLELY TO INVEST IN SECURITIES; (B) ANY LEGAL ENTITY WHICH FULFILS AT LEAST TWO OF THE FOLLOWING CRITERIA: (1) AN AVERAGE OF AT LEAST 250 EMPLOYEES DURING THE LAST FINANCIAL YEAR; (2) A TOTAL BALANCE SHEET OF MORE THAN €43,000,000 AND (3) AN ANNUAL NET TURNOVER OF MORE THAN €50,000,000, AS SHOWN IN THE ENTITY'S LAST ANNUAL OR CONSOLIDATED ACCOUNTS; OR

(C) IN ANY OTHER CIRCUMSTANCES WHICH DO NOT REQUIRE THE PUBLICATION BY THE COMPANY OF A PROSPECTUS PURSUANT TO ARTICLE 3(2) OF THE PROSPECTUS DIRECTIVE.

LIKEWISE, THIS PRESS RELEASE IS ONLY BEING DISTRIBUTED TO, AND IS ONLY DIRECTED AT, PERSONS IN THE UNITED KINGDOM THAT ARE QUALIFIED INVESTORS AS THAT TERM IS DEFINED IN THE PROSPECTUS DIRECTIVE THAT ARE ALSO (I) "INVESTMENT PROFESSIONALS" FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICE AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR (II) "HIGH NET WORTH ENTITIES" AND OTHER PERSONS TO WHOM IT MAY LAWFULLY BE COMMUNICATED, FALLING WITHIN THE MEANING OF ARTICLE 49(2)(A) TO (D) OF THE ORDER (ALL SUCH PERSONS BEING "RELEVANT PERSONS"). THE SHARES ARE ONLY AVAILABLE TO RELEVANT PERSONS AND ANY INVITATION, OFFER OR AGREEMENT TO SUBSCRIBE, PURCHASE OR OTHERWISE ACQUIRE SUCH SHARES WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. ANY PERSON WHO IS NOT A RELEVANT PERSON SHOULD NOT ACT OR RELY ON THIS DOCUMENT OR ANY OF ITS CONTENTS.

THIS PRESS RELEASE CANNOT BE PUBLISHED, DISTRIBUTED OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA. THIS PRESS RELEASE DOES NOT CONSTITUTE AND IS NOT PART OF AN OFFER OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR SHARES IN THE UNITED STATES. CELLECTIS' SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. CELLECTIS HAS NO INTENTION OF MAKING A PUBLIC OFFERING FOR ITS SHARES IN THE UNITED STATES.

THE DISTRIBUTION OF THIS DOCUMENT MAY, IN SEVERAL COUNTRIES, BE SUBJECT TO SPECIFIC REGULATIONS. PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT POTENTIAL LOCAL RESTRICTIONS AND COMPLY WITH THEM